SI-BONE revenue growth slows to 11% as operating loss narrows 32% on improved productivity

Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 6, 2025 · ~1 min read

Key Changes

• high

  Revenue grew 11% to $52.6M vs 25% prior year, driven by U.S. procedure volumes; operating loss improved 32% to $5.1M from $7.5M as revenue per territory sales manager rose 10% to $2.2M.

  MD&A: Financial Results verify on EDGAR →
• high

  Three platform technologies received FDA breakthrough device designation, a regulatory distinction signaling significant clinical innovation and potential for expedited review.

  MD&A: Innovation & Regulatory verify on EDGAR →
• medium

  Cumulative procedures performed increased 25% to nearly 150,000 from over 120,000 prior year; ASC/OBL procedure mix rose to 33% from 30%, expanding addressable market.

  MD&A: Market Adoption verify on EDGAR →